Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement

Similar Items

• Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis
  od: De Rycke, L, i dr.
  Izdano: (2005)
• Usefulness of anti-cyclic citrullinate peptide antibody determination in synovial fluid analysis of patients with rheumatoid arthritis
  od: G. Valesini, i dr.
  Izdano: (2011-09-01)
• Anti‐cyclic citrullinated peptide positivity in non‐rheumatoid arthritis disease samples: citrulline‐dependent or not?
  od: Vannini, A, i dr.
  Izdano: (2007)
• The effect of infliximab on rheumatoid factor and anti-citrullinated cyclic peptide antibodies
  od: van Damme, N, i dr.
  Izdano: (2002)
• The effect of etanercept on anti‐cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis
  od: Chen, H A, i dr.
  Izdano: (2006)